Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010

Chronic myeloid leukemia (CML) has paradigm shift in its treatment modality after the discovery of targeted therapy Imatinib. At our centre we collected data of 100 consecutive patients over a period of 8 years. The interesting finding in our study was difference in the survival of patients presenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansal, Shweta, Advani, S. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902615/
https://www.ncbi.nlm.nih.gov/pubmed/24516300
http://dx.doi.org/10.4103/0971-5851.123717
_version_ 1782301014294003712
author Bansal, Shweta
Advani, S. H.
author_facet Bansal, Shweta
Advani, S. H.
author_sort Bansal, Shweta
collection PubMed
description Chronic myeloid leukemia (CML) has paradigm shift in its treatment modality after the discovery of targeted therapy Imatinib. At our centre we collected data of 100 consecutive patients over a period of 8 years. The interesting finding in our study was difference in the survival of patients presenting in early chronic phase (81%) versus late chronic phase (16%). Also the patients with primary resistance did poorly compared to the patients who developed secondary resistance to Imatinib.
format Online
Article
Text
id pubmed-3902615
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-39026152014-02-10 Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010 Bansal, Shweta Advani, S. H. Indian J Med Paediatr Oncol Original Article Chronic myeloid leukemia (CML) has paradigm shift in its treatment modality after the discovery of targeted therapy Imatinib. At our centre we collected data of 100 consecutive patients over a period of 8 years. The interesting finding in our study was difference in the survival of patients presenting in early chronic phase (81%) versus late chronic phase (16%). Also the patients with primary resistance did poorly compared to the patients who developed secondary resistance to Imatinib. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3902615/ /pubmed/24516300 http://dx.doi.org/10.4103/0971-5851.123717 Text en Copyright: © Indian Journal of Medical and Paediatric Oncology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Bansal, Shweta
Advani, S. H.
Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010
title Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010
title_full Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010
title_fullStr Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010
title_full_unstemmed Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010
title_short Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010
title_sort report of chronic myelogenous leukemia in chronic phase from, asian institute of oncology, mumbai, 2002-2010
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902615/
https://www.ncbi.nlm.nih.gov/pubmed/24516300
http://dx.doi.org/10.4103/0971-5851.123717
work_keys_str_mv AT bansalshweta reportofchronicmyelogenousleukemiainchronicphasefromasianinstituteofoncologymumbai20022010
AT advanish reportofchronicmyelogenousleukemiainchronicphasefromasianinstituteofoncologymumbai20022010

Ejemplares similares